Physician profile
Chamaine Brooks
NPI 1619139029
$2,633.74
in general payments reported to CMS, 2019-2025
28 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $147 · 2021: $35.90 · 2022: $56.76 · 2023: $376 · 2024: $657 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.57 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $461.46 | 2021-2025 | Vraylar, Linzess |
| Ardelyx, INC. | $254.17 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $201.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.56 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $106.81 | 2019-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $103.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.88 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.04 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $74.76 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $70.62 | 2023-2025 | Rexulti |
| Amgen INC. | $68.75 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $54.27 | 2020-2021 | |
| Pfizer INC. | $54.11 | 2019-2020 | |
| Corcept Therapeutics | $46.50 | 2024 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.43 | 2019-2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $37.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $30.26 | 2019 | |
| Dynavax Technologies Corporation | $29.36 | 2024-2025 | Heplisav-B |
| Boston Scientific Corporation | $27.61 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Edwards Lifesciences Corporation | $18.51 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $16.37 | 2019 | |
| Dexcom, INC. | $15.55 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $14.82 | 2024 | |
| Eisai INC. | $14.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chamaine Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.